Value is all about what a company is worth versus what price it is
available for. If you went into a grocery store and all the bananas were on sale
at half price, they could be considered
In this section, we usually try to help investors determine whether Heyu Biological Technology is trading at an attractive price based on the cash flow it is expected to produce in the future. But as Heyu Biological Technology has not provided consistent financial data, and the stock also has no analyst forecast or coverage, its intrinsic value cannot be reliably calculated by extrapolating past data or using analyst consensus cash flow predictions.
This is quite a rare situation as 89% of companies covered by Simply Wall St do have a valuation analysis. You can see them here.
Show me the analysis anyway
INTRINSIC VALUE BASED ON FUTURE CASH FLOWS
It is not possible to calculate the future cash flow value for
Heyu Biological Technology. This is due to cash flow or dividend data being
unavailable. The share price is
PRICE RELATIVE TO MARKET
We can also value a company based on what the stock market is willing to pay for
it. This is similar to the price of fruit (e.g. Mangoes or Avocados) increasing
when they are out of season, or how much your home is worth.
The amount the stock market is willing to pay for
Heyu Biological Technology's
is considered below, and whether this is a fair price.
Price based on past earnings
Heyu Biological Technology's earnings available for a low price, and how does
this compare to other companies in the same industry?
In this section we usually present revenue and earnings growth projections based on the consensus estimates of professional analysts to help investors understand the company’s ability to generate profit. But as Heyu Biological Technology has not provided enough past data and has no analyst forecast, its future earnings cannot be reliably calculated by extrapolating past data or using analyst predictions.
This is quite a rare situation as 97% of companies covered by Simply Wall St do have past financial data. You can see them here.
Show me the analysis anyway
The future performance of a company is measured in the same way as past
performance, by looking at estimated
and how much profit it is expected to make.
Future estimates come from
professional analysts. Just like forecasting the weather, they don’t always get
Expected Software industry annual growth in earnings.
Earnings growth vs Low Risk Savings
Heyu Biological Technology
expected to grow at an
Unable to compare Heyu Biological Technology's earnings growth to the low risk savings rate as no estimate data is available.
Growth vs Market Checks
Unable to compare Heyu Biological Technology's earnings growth to the United States of America market average as no estimate data is available.
Unable to compare Heyu Biological Technology's revenue growth to the United States of America market average as no estimate data is available.
Unable to determine if Heyu Biological Technology is high growth as no earnings estimate data is available.
Unable to determine if Heyu Biological Technology is high growth as no revenue estimate data is available.
Past and Future Earnings per Share
The accuracy of the analysts who estimate the future performance data can
be gauged below. We look back 3 years and see if they were any good at
predicting what actually occurred. We also show the highest and lowest estimates
looking forward to see if there is a wide range.
While we do not consider unaudited financials to be a reliable enough to include in our analysis, you can access them on the OTC Markets Website. If you are looking for more of a qualitative research into the company, you can access Heyu Biological Technology's filings and announcements here.
All data from Heyu Biological Technology Company Filings, last reported 5 months ago, and in
Trailing twelve months (TTM)
annual period rather than quarterly.
OTCPK:HYBT Past Revenue, Cash Flow and Net Income Data
Date (Data in USD Millions)
Net Income *
*GAAP earnings excluding extraordinary items.
Performance last year
We want to ensure a company is making the most of what it has available. This is
done by comparing the return (profit) to a company's available
It is difficult to establish if Heyu Biological Technology has efficiently used shareholders’ funds last year (Return on Equity greater than 20%) due to its liabilities exceeding its assets.
Unable to establish if Heyu Biological Technology has efficiently used its assets last year compared to the US Software industry average (Return on Assets) as past financial data has not been reported.
It is difficult to establish if Heyu Biological Technology improved its use of capital last year versus 3 years ago (Return on Capital Employed) as it is currently loss-making.
Heyu Biological Technology's performance over the past 5 years by checking for:
Has earnings increased in past 5 years? (1 check)
Has the earnings growth in the last year exceeded that of the
industry? (1 check)
Is the recent earnings growth over the last year higher than the average annual growth over the
past 5 years? (1 check)
Is the Return on Equity (ROE) higher than 20%? (1 check)
Is the Return on Assets (ROA) above industry average? (1 check)
Has the Return on Capital Employed (ROCE) increased from 3 years ago? (1 check)
The above checks will fail if the company has reported a loss in the most recent
earnings report. Some checks require at least 3 or 5 years worth of data.
Heyu Biological Technology
has a total score of
0/6, see the detailed checks below.
Note: We use GAAP Net Income excluding extraordinary items in all our calculations.
A company's financial position is much like your own financial position,
it includes everything you own
The boxes below represent the relative size of what makes up
Heyu Biological Technology's finances.
The net worth of a company is the difference between its assets and liabilities.
Unable to compare short term assets to short term liabilities as Heyu Biological Technology has not reported sufficient balance sheet data.
Heyu Biological Technology has no long term commitments.
This treemap shows a more detailed breakdown of
Heyu Biological Technology's finances. If any of them are yellow this
indicates they may be out of proportion and red means they relate to one of the
Liabilities and shares
The 'shares' portion represents any funds contributed by the owners (shareholders) and any profits.
Unable to establish if Heyu Biological Technology has a high level of physical assets or inventory without balance sheet data.
Heyu Biological Technology has negative shareholder equity (liabilities exceed assets) therefore debt is not covered by short term assets.
Nearly all companies have debt. Debt in itself isn’t
however if the debt is too high, or the company can’t afford to pay the interest
on its debts this may have impacts in the future.
The graphic below shows equity (available funds) and debt, we ideally want to
see the red area (debt) decreasing.
If there is any debt we look at the companies capability to repay it, and
whether the level has increased over the past 5 years.
Management is one of the most important areas of a company. We look at
unreasonable CEO compensation, how long the team and board of directors have
been around for and insider trading.
TENURE AS CEO
Mr. Ban Siong Ang is Chairman of the Board, CEO and President at Heyu Biological Technology Corporation. Mr. Ang serves as the Chief Executive Officer, Chief Financial Officer, Managing Director, Secretary and Treasurer of Heyu Development and Management Corporation. Mr. Ang has been the Chief Executive Officer of Heyu Leisure Holidays Corporation since January 24, 2014 and has been its Group Managing Director since 2014 and serves as its Interim Chief Financial Officer. Mr. Ang served as the President and Chief Financial Officer of Heyu Leisure Holidays Corporation. He began his career at Bursa Stock Exchange in Malaysia. He has been involved in hotels and property development and management in China as a consultant since 2006. He founded the HEYU group of companies in Hong Kong and China in 2010. He holds several professional memberships in the United Kingdom. He has a background in the hotel and property development and management field. He has been a Director of Heyu Leisure Holidays Corporation since January 13, 2014. He has been a Director of Heyu Development and Management Corporation since September 17, 2014. Mr. Ang received his Bachelor Degree in Information Technology from the University of Southern Queensland, Australia and received his Masters of Business Administration and Doctor of Business Administration Degrees from Ansted University.
Insufficient data for Ban to compare compensation growth.
Insufficient data for Ban to establish whether their remuneration is reasonable compared to companies of similar size in United States of America.
Heyu Biological Technology Corporation does not have significant operations. It focuses on a merger or acquisition with an unidentified company or companies. Previously, the company was engaged in the provision of application services; and development of business software technologies and services for business merchants and organizations. The company was formerly known as Pacific WebWorks, Inc. and changed its name to Heyu Biological Technology Corporation in June 2018. Heyu Biological Technology Corporation was founded in 1987 and is based in Xiamen, the People's Republic of China.
Simply Wall Street Pty Ltd (ACN 600 056 611), is a Corporate Authorised Representative (Authorised Representative Number: 467183) of Sanlam Private Wealth Pty Ltd (AFSL No. 337927). Any advice contained in this website is general advice only and has been prepared without considering your objectives, financial situation or needs. You should not rely on any advice and/or information contained in this website and before making any investment decision we recommend that you consider whether it is appropriate for your situation and seek appropriate financial, taxation and legal advice. Please read our Financial Services Guide before deciding whether to obtain financial services from us.